Pulmonary nontuberculous mycobacterial disease in a patient with chronic hepatitis C treated with pegylated interferon .ALPHA.2a and ribavirin

DOI Web Site Web Site 47 References

Bibliographic Information

Other Title
  • Ｃ型慢性肝炎に対するペグインターフェロンとリバビリン併用療法中に肺非結核性抗酸菌症を発症した１例
  • 症例報告 C型慢性肝炎に対するペグインターフェロンとリバビリン併用療法中に肺非結核性抗酸菌症を発症した1例
  • ショウレイ ホウコク Cガタ マンセイ カンエン ニ タイスル ペグインターフェロン ト リバビリン ヘイヨウ リョウホウ チュウ ニ ハイ ヒケッカクセイ コウサンキンショウ オ ハッショウ シタ 1レイ
  • Pulmonary nontuberculous mycobacterial disease in a patient with chronic hepatitis C treated with pegylated interferon α2a and ribavirin

Search this article

Description

Pegylated interferon (PEG-IFN) in combination with ribavirin (RBV) has been widely used for the treatment of chronic hepatitis C. One of common adverse effects of PEG-IFN/RBV therapy is leukopenia which may cause cell-mediated immunosuppression. Here, we report a case of pulmonary nontuberculous mycobacterial disease occurring in a patient with chronic hepatitis C during PEG-IFN/RBV therapy.<br> A 62-year-old woman with chronic hepatitis C reported a persistent cough 24 weeks after start of PEG-IFN/RBV therapy. Chest X ray and computed tomography demonstrated a nodular lesion in the lingula of her left lung. Bronchoalveolar lavage yielded positive microscopic search of acid-fast bacilli which was identified as Mycobacterium avium by polymerase chain reaction.<br> Although it is unclear whether PEG-IFN/RBV therapy could play a role in the onset of Mycobacterium avium lung disease in our case, clinicians should keep this disease in mind during the treatment of chronic hepatitis C with PEG-IFN and RBV.<br>

Journal

  • Kanzo

    Kanzo 52 (12), 770-776, 2011

    The Japan Society of Hepatology

References(47)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top